NASDAQ · Drug Manufacturers - Specialty & Generic
AMPH (AMPH) Stock
$20.22
+1.40%
NASDAQ: AMPH
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
AMPH: Lowering target price to $18.00
Argus Research · Jul 15, 2026
1 of Wall Street’s Favorite Stocks to Research Further and 2 Facing Challenges
StockStory · Jul 10, 2026
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
Zacks · Jul 10, 2026
Amphastar Unit Receives US FDA Warning Letter on Violations at California Facility
MT Newswires · Jul 8, 2026
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Investing.com · Jun 29, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held29.74%
Institutions Held77.27%
Institutions Float Held109.98%
Peer Comparison
About AMPH
AMPH is led by CEO Yongfeng Zhang, employs 2,028 people, headquartered in US, publicly traded since 2014.
AMPH stock trades at $20.22 with a market capitalization of $891.56M. The stock is valued at a price-to-earnings (P/E) ratio of 12.02, price-to-book of 1.15, price-to-sales of 1.22. Over the past 52 weeks the stock has ranged between $16.65 and $31.26, and currently trades 35.3% below its 52-week high.
On profitability, AMPH generates a return on equity (ROE) of 10.39%, return on capital employed of 17.74%, an operating margin of 16.20%, a net profit margin of 11.00%.